Following a Q320 rebound in elective procedures sparking a return to growth for the COVID-ravaged Spine market, the recent COVID resurgence has once again dragged US Spine growth rates down. While many companies have yet to report Q420 earnings, early signs point to a downturn, with procedure volumes impacted by hospital resource utilization and renewed restrictions around elective procedures.
In this article, Julianne Burns, SmartTRAK's GM, Spine, looks at the following topics:
- The COVID Impact Update
- Shifts in Cervical Total Disc Replacement (cTDR)
- Growth in Prone Lateral Procedures
- Expansion in SI Joint Fusion
- Innovation in Interbody Materials